BioCentury | Dec 7, 2016
Translation in Brief

Mighty mitochondria

...using the Mitomic Technology platform it obtained through its 2014 acquisition of Mitomics Inc. Mitton said Mitomics...
...DNA from pseudogenes that also contain small repeating sequences characteristic of mitochondrial DNA. However, because Mitomics...
...said MDNA’s first order of business was to validate the 3.4 kB mitochondrial DNA deletion Mitomics...
BioCentury | Nov 11, 2016
Company News

MDNA, University of Oxford deal

MDNA and the university partnered to develop a non-invasive blood test for endometriosis using MDNA’s Mitomic Technology. MDNA says the companies plan to launch the test next year. The university did not respond to inquiries,...
BioCentury | Oct 21, 2013
Company News

Bioceros, 4SC, Genedata, Horizon Discovery cardiovascular, genomics, gene/cell therapy news

The CV genes-at-target consortium led by German Heart Center Munich (Munich, Germany) received a €5.8 million ($7.8 million) grant from the EU's Framework Programme 7 (FP7) to evaluate genomic risk loci for coronary artery disease...
BioCentury | Oct 15, 2012
Company News

Mitomics, LabCorp sales and marketing update

...Core Mitomic Test . The test will be performed at Mitomics' CLIA-certified laboratory. Last year, Mitomics...
...a cancerization field effect by detecting large-scale mitochondrial DNA deletions in non-malignant prostate needle biopsies. Mitomics...
...to provide financial details, while LabCorp could not be reached (see BioCentury, April 11, 2011). Mitomics Inc....
BioCentury | Jul 16, 2012
Company News

Horizon Discovery Ltd., Bayer deal

Horizon and Bayer collaborated to develop human isogenic cell lines using Horizon's Genesis genome editing technology for use in Bayer's cancer R&D programs. Horizon said it aims to develop cell lines that accurately model relevant...
BioCentury | Feb 20, 2012
Company News

LabMD Inc., Mitomics sales and marketing update

...granted LabMD non-exclusive, U.S. commercialization rights to Mitomics' Prostate Core Mitomic Test . Last year, Mitomics...
...biopsies. Terms were not disclosed (see BioCentury, April 11, 2011). LabMD Inc. , Atlanta, Ga. Mitomics Inc....
BioCentury | Jun 27, 2011
Company News

Transgenomic sales and marketing update

Transgenomic launched its Nuclear Mitome Test to identify mutations associated with mitochondrial disorders. Transgenomic Inc. (OTCBB:TBIO), Omaha, Neb. Business: Diagnostic WIR Staff Diagnostic...
BioCentury | May 30, 2011
Company News

Mitomics, QDx Pathology Services Inc. sales and marketing update

...QDx received non-exclusive rights from Mitomics to develop and commercialize the mitochondrial marker behind Mitomics' prostate...
...cells. QDx will use the marker to develop its early stage QPredict Prostate Mitomic Test. Mitomics...
...launched PCMT in the U.S. in March. Terms were not disclosed (see BioCentury, April 11). Mitomics Inc....
BioCentury | Apr 11, 2011
Company News

Mitomics sales and marketing update

...determine the presence or absence of cancerous cells and is available through Mitomics' CLIA-certified laboratory. Mitomics Inc....
BioCentury | Feb 21, 2011
Company News

Mitomics management update

Mitomics Inc. , Thunder Bay, Ontario Business: Diagnostic Hired: Luis Martin as chief commercial officer, formerly director for product development at PREVENT, a national center of excellence for the commercialization of novel vaccine technologies WIR Staff...
Items per page:
1 - 10 of 11
BioCentury | Dec 7, 2016
Translation in Brief

Mighty mitochondria

...using the Mitomic Technology platform it obtained through its 2014 acquisition of Mitomics Inc. Mitton said Mitomics...
...DNA from pseudogenes that also contain small repeating sequences characteristic of mitochondrial DNA. However, because Mitomics...
...said MDNA’s first order of business was to validate the 3.4 kB mitochondrial DNA deletion Mitomics...
BioCentury | Nov 11, 2016
Company News

MDNA, University of Oxford deal

MDNA and the university partnered to develop a non-invasive blood test for endometriosis using MDNA’s Mitomic Technology. MDNA says the companies plan to launch the test next year. The university did not respond to inquiries,...
BioCentury | Oct 21, 2013
Company News

Bioceros, 4SC, Genedata, Horizon Discovery cardiovascular, genomics, gene/cell therapy news

The CV genes-at-target consortium led by German Heart Center Munich (Munich, Germany) received a €5.8 million ($7.8 million) grant from the EU's Framework Programme 7 (FP7) to evaluate genomic risk loci for coronary artery disease...
BioCentury | Oct 15, 2012
Company News

Mitomics, LabCorp sales and marketing update

...Core Mitomic Test . The test will be performed at Mitomics' CLIA-certified laboratory. Last year, Mitomics...
...a cancerization field effect by detecting large-scale mitochondrial DNA deletions in non-malignant prostate needle biopsies. Mitomics...
...to provide financial details, while LabCorp could not be reached (see BioCentury, April 11, 2011). Mitomics Inc....
BioCentury | Jul 16, 2012
Company News

Horizon Discovery Ltd., Bayer deal

Horizon and Bayer collaborated to develop human isogenic cell lines using Horizon's Genesis genome editing technology for use in Bayer's cancer R&D programs. Horizon said it aims to develop cell lines that accurately model relevant...
BioCentury | Feb 20, 2012
Company News

LabMD Inc., Mitomics sales and marketing update

...granted LabMD non-exclusive, U.S. commercialization rights to Mitomics' Prostate Core Mitomic Test . Last year, Mitomics...
...biopsies. Terms were not disclosed (see BioCentury, April 11, 2011). LabMD Inc. , Atlanta, Ga. Mitomics Inc....
BioCentury | Jun 27, 2011
Company News

Transgenomic sales and marketing update

Transgenomic launched its Nuclear Mitome Test to identify mutations associated with mitochondrial disorders. Transgenomic Inc. (OTCBB:TBIO), Omaha, Neb. Business: Diagnostic WIR Staff Diagnostic...
BioCentury | May 30, 2011
Company News

Mitomics, QDx Pathology Services Inc. sales and marketing update

...QDx received non-exclusive rights from Mitomics to develop and commercialize the mitochondrial marker behind Mitomics' prostate...
...cells. QDx will use the marker to develop its early stage QPredict Prostate Mitomic Test. Mitomics...
...launched PCMT in the U.S. in March. Terms were not disclosed (see BioCentury, April 11). Mitomics Inc....
BioCentury | Apr 11, 2011
Company News

Mitomics sales and marketing update

...determine the presence or absence of cancerous cells and is available through Mitomics' CLIA-certified laboratory. Mitomics Inc....
BioCentury | Feb 21, 2011
Company News

Mitomics management update

Mitomics Inc. , Thunder Bay, Ontario Business: Diagnostic Hired: Luis Martin as chief commercial officer, formerly director for product development at PREVENT, a national center of excellence for the commercialization of novel vaccine technologies WIR Staff...
Items per page:
1 - 10 of 11